

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CHINA ISOTOPE & RADIATION CORPORATION

中國同輻股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 1763)

VOLUNTARY ANNOUNCEMENT CNGT OFFICIALLY POSSESSING THE PRODUCTION AND SUPPLY CAPACITY OF 10,000-CURIE GMP-GRADE LUTETIUM-177 AND OTHER NUCLIDES

This announcement is made on a voluntary basis by China Isotope & Radiation Corporation (the “**Company**”) to keep shareholders and potential investors informed of the latest business developments of the Company.

The board of directors (the “**Board**”) of the Company is pleased to announce that, recently, the first carrier-free lutetium-177 GMP production line with annual production capacity of 10,000-curie-grade in China and germanium and gallium 68Ge-68Ga generator production line with annual production capacity of 1,000-grade were fully completed and put into operation, marking the realization of the localized and large-scale commercial supply of GMP-grade lutetium-177 and gallium-68 medical nuclides. The successful commissioning of the production lines will effectively alleviate the problem of insufficient supply of domestic lutetium-177 and gallium-68 and the heavy reliance on imports.

The lutetium-177 and gallium-68 products of Chengdu Gaotong Isotope Co., Ltd. (“**CNGT**”), a subsidiary of the Company, have satisfied the requirements of EMA standards in terms of production line design, production technology, quality indicators, equipment and facilities, management system, etc., and have achieved the first echelon level in the world, with obvious international competitive advantages. In the future, CNGT will enter the international market and participate in the international medical nuclide industry chain cycle.

At the same time, CNGT can also officially supply two new nuclides, namely curie-level terbium-161 and scandium-47, which have similar decay, biochemical and in-vivo properties with lutetium-177, and also have unique advantages, bringing new opportunities and possibilities for the development of nuclear medicine.

By order of the Board
China Isotope & Radiation Corporation
Zhang Junqi
Chairman

Beijing, the PRC, 22 April 2024

As at the date of this announcement, the Board comprises Mr. Zhang Junqi, Mr. Xu Hongchao and Mr. Fan Guomin as executive Directors; Mr. Chen Shoulei, Mr. Ding Jianmin, Ms. Chang Jinyu and Ms. Liu Xiuhong as non-executive Directors; and Mr. Poon Chiu Kwok, Mr. Tian Jiahe, Ms. Chen Jingshan and Mr. Lu Chuang as independent non-executive Directors.